Jensen, D. M. & Ascione, A. Future directions in therapy for chronic hepatitis C. Antivir. Ther. 13 (Suppl. 1), 31–36 (2008). Vertex. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir ...

Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...